0.92
-0.0086(-0.93%)
Currency In USD
| Previous Close | 0.93 |
| Open | 0.9 |
| Day High | 0.94 |
| Day Low | 0.89 |
| 52-Week High | 3.1 |
| 52-Week Low | 0.81 |
| Volume | 3,168 |
| Average Volume | 22,811 |
| Market Cap | 11.02M |
| PE | -0.54 |
| EPS | -1.7 |
| Moving Average 50 Days | 0.95 |
| Moving Average 200 Days | 1.62 |
| Change | -0.01 |
If you invested $1000 in Indaptus Therapeutics, Inc. (INDP) since IPO date, it would be worth $1.91 as of February 05, 2025 at a share price of $0.917. Whereas If you bought $1000 worth of Indaptus Therapeutics, Inc. (INDP) shares 5 years ago, it would be worth $40.94 as of February 05, 2025 at a share price of $0.917.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Jan 13, 2025 1:00 PM GMT
NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entere
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
GlobeNewswire Inc.
Jan 08, 2025 1:00 PM GMT
Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotech
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
GlobeNewswire Inc.
Nov 22, 2024 1:36 PM GMT
NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entere